top of page

Adult DRV/r (400/50mg) FAQs for Communities and PLHIV

  • hivtoolkit
  • Apr 13, 2022
  • 1 min read

CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50 mg) and expanding access to this best-in-class medicine for people living with HIV needing a PI. Categories covered include treatment failure, protease inhibitors, an overview of DRV/r, DRV/r sequencing, and side effects.






댓글


  • LinkedIn
  • Facebook
  • Twitter
  • Instagram
  • YouTube

383 Dorchester Avenue, Suite 400

Boston, MA 02127

The goal of the HIV New Product Introduction Toolkit is to stimulate conversations between government, partners, and communities on new product introduction. Please feel free to share any thoughts, questions, or additional resources for consideration by contacting us via email at HIVToolkit@clintonhealthaccess.org.

 

© 2022  Clinton Health Access Initiative - Global HIV Access Program

bottom of page